McLaughlin Asset Management Inc. bought a new position in Stryker Corporation (NYSE:SYK – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 2,183 shares of the medical technology company’s stock, valued at approximately $767,000.
A number of other institutional investors have also recently made changes to their positions in SYK. Vancity Investment Management Ltd purchased a new position in Stryker in the fourth quarter worth about $229,000. T. Rowe Price Investment Management Inc. lifted its stake in shares of Stryker by 733.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 64,607 shares of the medical technology company’s stock valued at $22,708,000 after purchasing an additional 56,855 shares during the last quarter. Compound Planning Inc. boosted its holdings in shares of Stryker by 69.2% in the 4th quarter. Compound Planning Inc. now owns 6,443 shares of the medical technology company’s stock worth $2,264,000 after purchasing an additional 2,636 shares during the period. Claris Financial LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $358,000. Finally, Axxcess Wealth Management LLC raised its holdings in Stryker by 71.0% during the 4th quarter. Axxcess Wealth Management LLC now owns 8,194 shares of the medical technology company’s stock valued at $2,880,000 after buying an additional 3,401 shares during the period. Institutional investors own 77.09% of the company’s stock.
Analysts Set New Price Targets
Several research firms have commented on SYK. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Canaccord Genuity Group lowered their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Leerink Partners cut their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Truist Financial reissued a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Evercore set a $355.00 price objective on shares of Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.
Stryker Stock Performance
Stryker stock opened at $308.62 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market capitalization of $118.31 billion, a PE ratio of 35.72, a P/E/G ratio of 1.93 and a beta of 0.78. The company has a 50 day moving average price of $314.43 and a 200-day moving average price of $341.94. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.
Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.
Stryker Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.
Insider Activity at Stryker
In other news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This represents a 95.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 323,264 shares of company stock worth $100,659,489 over the last three months. 4.60% of the stock is owned by corporate insiders.
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
- Five stocks we like better than Stryker
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
